Roche’s Hivid
Executive Summary
Company offering rebates matching federal funds to state AIDS drug programs for ddC (zalcitabine). To date, New Jersey and Texas have signed on to the program, which offers rebates equal to those required under Medicaid to state AIDS Drug Reimbursement Programs or AIDS Drug Assistance Programs that receive federal Ryan White funding and submit quarterly reports to Roche on the number of patients enrolled and taking Hivid. Roche also has an Indigent Patient Program.